|Drs. Luis Salicrup (l) and Mark Parascandola
Scientists at NCI, working with embassy colleagues at the State Department, will provide scientific and technical expertise to government and private sector groups in China and Turkey.
Dr. Mark Parascandola, an epidemiologist in the Tobacco Control Research Branch, has been designated an embassy fellow at the U.S. embassy in Beijing, China.
Lung cancer incidence is high among both men and women in China and is the most frequently diagnosed type of cancer. Yet only 2.4 percent of women in China smoke—compared with 53 percent of men. Factors such as secondhand smoke may contribute to the high rates of lung cancer among non-smoking women in China. The China National Health and Family Planning Commission and the China Center for Disease Control are among groups working to address these health risks, through public education and community outreach programs.
Parascandola will work with U.S. experts to develop public-private partnerships that support the Chinese initiatives for smoke-free workplaces and tobacco control through cancer hospitals. He will also provide technical expertise and guidance in advance of the China-U.S. Smoke-free Workplace Initiative rollout, which is expected to launch this spring. This program has already enlisted the support of more than 150 companies in China that are invested in creating smoke-free workplaces for their employees. He will also support tobacco control protocols at regional cancer hospitals, which are being developed by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences.
A second embassy fellow, Dr. Luis Salicrup, is an international cancer research specialist at NCI’s Center for Global Health who will work at the U.S. embassy in Ankara, Turkey.
Scientific research and development are important priorities in Turkey. The Scientific and Technological Research Council of Turkey (TUBITAK) is the lead agency for management and funding of research projects in Turkey. TUBITAK officials, working with diplomats at the U.S. Embassy, have requested the collaborative support of NCI and other NIH institutes and centers in the areas of innovation, transfer of cancer-related technologies and international research and development.
Salicrup will work with members of TUBITAK and colleagues in the embassy to create programs in research and development, knowledge management, technology transfer, commercialization of research, intellectual property and clinical trials. He will also provide guidance on developing public-private partnerships.—Linda Perrett